In vitro susceptibility profiles of 58 Paecilomyces clinical isolates are reported. Amphotericin B, itraconazole, and echinocandins showed poor activity against Paecilomyces lilacinus, while the new triazoles were active against it. Paecilomyces variotii exhibited a different susceptibility pattern, being susceptible to most antifungal agents apart from voriconazole and ravuconazole.
Sequence analysis. Sequences were assembled and edited using the SeqMan II and EditSeq software packages (Lasergene; DNAStar, Inc., Madison, WI). Sequence analysis was performed by comparing the DNA sequences with the ITS sequences of P. lilacinus AY213665 (ATCC 10114) and P. variotii AY753328 (CBS 102.74) and AY373941 (ATCC 22319) obtained from the GenBank database (http://www.ncbi.nlm.nih.gov/Genbank/).
Phylogenetic analysis. All phylogenetic analyses were conducted with InfoQuest FP software v4.50 (Bio-Rad Laboratories, Madrid, Spain) using the maximum parsimony clustering method. Phylogram stability was assessed by parsimony bootstrapping with 2,000 simulations. The ITS sequence of Rhizopus oryzae CNM-CM-4875 (Mold Collection of the Spanish National Center for Microbiology) was used as the outgroup.
Antifungal susceptibility testing. Microdilution testing was performed by following the EUCAST document (http: //www.escmid.org/Files/EUCAST%20moulds%20discussion% bp20document_071019.pdf) (1, 12, 17, 18) . Aspergillus fumigatus ATCC 2004305 and Aspergillus flavus ATCC 2004304 were used as quality control strains (14) .
The antifungal agents used were amphotericin B (AMB) (Sigma Aldrich Química), itraconazole (ITC) (Janssen S.A., Madrid, Spain), voriconazole (VOR) (Pfizer S.A., Madrid, Spain), ravuconazole (RVC) (Bristol-Myers Squibb, Princeton, NJ), posaconazole (POS) (Schering-Plough Research Institute, Kenilworth, NJ), terbinafine (TRB) (Novartis, Basel, Switzerland), caspofungin (Merck & Co., Inc., Rahway, NJ), micafungin (Astellas Pharma Inc., Tokyo, Japan), and anidulafungin (Pfizer S.A). The endpoint for AMB, ITC, VOR, RVC, POS, and TRB was the antifungal concentration that produced a complete inhibition of visual growth at 48 h. For the echinocandins, the endpoint was the antifungal concentration that produced a visible change in the morphology of the hyphae compared with that of the growth control well (minimum effective concentration [MEC]) (3, 11) .
Twenty-seven strains were identified as P. lilacinus and 31 as P. variotii by means of studying the morphology (7). In 20 cases, species were identified also by molecular methods as described above and invariably matched morphological identifications (Fig. 1) .
Susceptibility data and MIC distribution are displayed in Table 1 . P. lilacinus showed high MICs of AMB, ITC, and echinocandins with geometric means (GM) of MICs/MECs of Ͼ8 mg/liter. In contrast, VOR, POS, and TRB were active against this species (GM of MICs, Ͻ2 mg/liter), with POS being the drug with the best in vitro activity (GM, 0.28 mg/liter). P. variotii showed a different susceptibility pattern; the GM of MICs/MECs were Ͻ2 mg/liter for AMB, ITC, POS, TRB, and echinocandins. Although the GM of MICs for TRB were Ͻ2 mg/liter, 18 out of 27 strains showed MICs of Ն2 mg/liter. In addition, 22 out of 27 (81.5%) strains showed MICs of Ն2 mg/liter for VOR. A similar pattern was observed for RVC, for which 21 out of 27 (77.8%) strains had MICs of Ն2 mg/liter.
Limited information about the in vitro antifungal activities for these species is available in the literature, and an optimal treatment has not been established. In addition, some reports show susceptibility results per genus but not species, as well as MICs determined by different methods, which make results incomparable (15) .
We have reviewed here the antifungal susceptibility data of 58 Paecilomyces clinical isolates. P. lilacinus and P. variotii showed different susceptibility profiles to the antifungal drugs tested. Our results are in agreement with previous findings for P. lilacinus, except for echinocandins for which contradictory data have been reported (8, 15, 20) . Regarding cross-resistance to azole drugs, our data indicate that it is not predictable and all available azoles should be tested in order to set the susceptibility profile of each isolate.
Due to very little data concerning the antifungal susceptibility profiles for these species, this work will contribute toward establishing an optimal antifungal therapy for these fungi. VOR alone or in combination with TRB has been successfully used for the treatment of P. lilacinus oculomycosis and cutaneous or subcutaneous infection (16) . AMB seems to be the treatment of choice for P. variotii infections, and VOR resistance has been described previously (6) . According our data, new triazoles and TRB constitute the most promising alternatives for the treatment of P. lilacinus infections. In contrast, with the exception of VOR and RVC, all drugs tested against P. variotii showed good in vitro activity.
Since they have different susceptibility profiles, correct characterization of these species is compulsory. Our study shows that both morphological and molecular identification methods are useful for distinguishing these species as the ITSs are good targets for molecularly characterizing these organisms. 
